

data protection and privacy

At Dexcom,¹ we make it possible for patients and healthcare professionals (HCPs) to access and share glucose data to enable optimal diabetes management and care, simply and securely.

BENEFITS OF CGM USE

Continuous Glucose Monitoring (CGM) is a diabetes management tool proven to reduce both HbA1c while decreasing time spent in hypoglycemia—and patients experience these benefits regardless of insulin delivery method.^{1,2} Unlike a blood glucose meter, which provides just a single reading, CGM provides continuous, dynamic real-time information about a user's glucose levels. With readings every five minutes—up to 288 readings a day—patients will know where their glucose is headed and how fast it's getting there.

DEXCOM CGM SYSTEM

Our Dexcom CGM System is a medical device that includes a wearable and an app and/or optional receiver. Data is collected by the wearable where the glucose value is computed and encrypted. That encrypted data is transmitted over secure bluetooth to the Dexcom CGM app and/or optional receiver. Patients can view data, securely and privately.

DATA IN THE CLOUD


While the Dexcom CGM app allows for standalone use, patients who consent can take advantage of our cloud-based products including the Dexcom Follow app and Dexcom Clarity, in countries where available. Our products will transmit, process, and store glucose data on secure servers located within Bureau Veritas certified cloud services in the European Union (EU).

SECURE SHARING OF PATIENT DATA

Patients have several options to share their glucose data with healthcare professionals (HCP) and other authorized third-party apps and devices. Patients using Dexcom Clarity at home can print or email reports to their HCP, or can authorize to share their CGM data through the secure Dexcom Cloud. HCPs have continuous access to shared CGM data until revoked by the patient. HCPs can also access a single-use and anonymous upload of receiver contents that is not saved in Dexcom Clarity after the session. Patients also have the option of sharing their data with other trusted third party Dexcom Partners through the Dexcom API. Sharing can be revoked at any time.

PATIENT CONSENT, AUTHENTICATION, AND AUTHORIZATION

For a patient's CGM data to exist in the Dexcom Cloud and be visible to the patient, their HCP or EU-based Dexcom technical support staff, a patient's advanced consent is required. Access to patient data is subject to account authentication and sharing authorizations. Sharing can be revoked, and patients can request the permanent removal of their CGM data from the Dexcom Cloud, or exercise any other data subject right, anytime by emailing privacy@dexcom.com



- ↔ Data flows over industry standard secure TLS Transmission Protocol
- Push notification using the secure Google service Firebase Cloud Messaging
- ↔ Mutually authenticated communication data stream using AES 128 bit encrypted key
- - - Optional cloud-based features

- △ Identity/Oauth2 patient data retrieval
- Identity/Oauth2 Clarity home receiver upload
- Identity/authentication automated data upload
- ◇ Optional manual USB receiver uploads
(all receiver communication uses certificate based device authentication)
- ☆ Receiver uploads for clinical use
(all receiver communication uses certificate based device authentication)
- ⊖ Automatic data upload secure bluetooth

Learn more about our privacy policy and terms of use at: dexcom.com/global

DexCom, International, Ltd. and its affiliated European entities. 1 Tanfield, Suite 6, Level 1 Tanfield, Edinburgh EH3 5DA
 *DexCom, International, Ltd. and its affiliated European entities. 1 Beck RW, Riddlesworth TD, Ruedy KJ, et al. Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. [published online ahead of print July 12, 2017]. The Lancet Diabetes & Endocrinology. doi: [http://dx.doi.org/10.1016/S2213-8587\(17\)30217-6](http://dx.doi.org/10.1016/S2213-8587(17)30217-6). 2 Soupal J, Petruzelkova L, Flekac M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.
 Dexcom, Dexcom Clarity, Dexcom SHARE, Dexcom Follow, Dexcom G6 are registered trade marks of Dexcom, Inc. in the US and may be registered in other countries. ©2022 Dexcom Inc. All rights reserved. LBL015357 REV005

